# Sources — Flannery O'Connor

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. "Peacocks and the Red Wolf." *The Pharos* of Alpha Omega Alpha, Spring 2019:27–32. An article by two rheumatologists drawing on her letters (*The Habit of Being*) and the standard biography (*Flannery: A Life of Flannery O'Connor*). Supports her birth in Savannah on March 25, 1925, the only child of Edward Francis O'Connor and Regina Cline; her father's lupus, diagnosed in 1937, beginning with a whitish patch on his forehead and arthritis and first diagnosed as rheumatoid arthritis, and his death a month after his 45th birthday when she was 15; the Iowa Writers' Workshop and *Wise Blood* (1952); a month-long hospital stay in December 1949 with surgery for a floating kidney; joint pain in Connecticut in 1950 with suspected rheumatoid arthritis; the train journey home in December 1950, admission in Milledgeville, transfer on a kidney specialist's advice to Emory Hospital in Atlanta, and a positive LE cell test; her mother's decision to conceal the diagnosis and her learning it from a friend in mid-1951; discharge on daily ACTH injections; "practically bald-headed on top" with "a watermelon face" in January 1953; a limp and hip pain by early 1954, "subsequently attributed to avascular necrosis of the femoral head," crutches for most of her remaining years, and her letter that "my bone disintegration is being caused by the steroid drugs"; steroid tapering in 1961 with chloroquine; anemia from a bleeding fibroid and a hysterectomy at the turn of 1964, a lupus flare, kidney involvement and a halved prednisone dose; and her death on August 3, 1964, at 39. It also proposes, from letters and photographs, an early malar rash and Jaccoud arthropathy. https://www.alphaomegaalpha.org/wp-content/uploads/2021/03/2019-2-Silver.pdf
2. PBS, *American Masters*. "Flannery O'Connor: biographical timeline." Supports her birth in Savannah; her father's death "from lupus complications" in 1941; college in Milledgeville and Iowa; her return to Georgia in 1950, "not feeling well," and diagnosis with disseminated lupus erythematosus; the move to Andalusia; *Wise Blood*, *A Good Man Is Hard to Find*, and the posthumous National Book Award; surgery for a fibroid tumor in 1964 that reactivated her lupus; and her death in Baldwin County Hospital on August 3, 1964. https://www.pbs.org/wnet/americanmasters/flannery-oconnor-biographical-timeline/17555/
3. New Georgia Encyclopedia. "Flannery O'Connor (1925–1964)," by a Georgia College scholar (published 2002, edited August 3, 2023). Supports her birth to Regina Cline and Edward F. O'Connor; that at fifteen she "lost her father to systemic lupus erythematosus"; that she was "stricken with lupus" in 1950; her life at Andalusia from 1951 to 1964; that "an early 1964 surgery for a fibroid tumor reactivated O'Connor's lupus, which had been in remission"; and her death on August 3, 1964, in the Baldwin County Hospital. https://www.georgiaencyclopedia.org/articles/arts-culture/flannery-oconnor-1925-1964/
4. "O'Connor, Flannery." *Scribner Encyclopedia of American Lives, Thematic Series: The 1960s*, on Encyclopedia.com. Supports her birth as Mary Flannery O'Connor and dates; her father's lupus; that "doctors in Atlanta diagnosed her condition as lupus"; "massive injections of ACTH"; that "her hipbones could not support her weight, and she was forced to use aluminum crutches"; the move to Andalusia; an abdominal tumor removed in early 1964 that "was benign, but the procedure reactivated the lupus, and her kidneys were affected"; and death from kidney failure in Milledgeville. https://www.encyclopedia.com/humanities/encyclopedias-almanacs-transcripts-and-maps/oconnor-flannery
5. "Dances with wolves." *Hektoen International*, Spring 2016. A medical humanities essay quoting her letters: an operation for a floating kidney in 1949; diagnosis at 25; ACTH injections she gave herself; her father's lupus diagnosed in 1937 and his death in 1941. https://hekint.org/2017/01/29/dances-with-wolves/
6. "Lupus in the mid-20th century: the life and death of Flannery O'Connor." *J Clin Rheumatol* 2011;17(5):266–268. PMID 21778907. Bibliographic record only (no abstract); cited by source 1. https://pubmed.ncbi.nlm.nih.gov/21778907/
7. "Flannery O'Connor's lupus. A commentary on her collected letters, The Habit of Being." *JAMA* 1980;244(13):1441–1442. PMID 6999184. Bibliographic record only. https://pubmed.ncbi.nlm.nih.gov/6999184/
8. HISTMED Master Roster v3. Internal project source. Its claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2019;71(9):1400–1412. PMID 31385462 (abstract read): ANA of 1:80 or higher as the entry criterion; weighted clinical and immunologic domains; classification at 10 points or more. https://pubmed.ncbi.nlm.nih.gov/31385462/
2. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis* 2024;83(1):15–29. PMID 37827694 (abstract read): hydroxychloroquine for all patients at 5 mg/kg real body weight a day; glucocorticoids as bridging therapy, minimized to 5 mg a day or less for maintenance and withdrawn when possible; prompt immunosuppressive drugs and biologics (belimumab, anifrolumab) to allow tapering; for active lupus nephritis, glucocorticoids with mycophenolate or low-dose cyclophosphamide, with belimumab or a calcineurin inhibitor (voclosporin or tacrolimus) as add-on; prevention of infection, osteoporosis, and cardiovascular disease. https://pubmed.ncbi.nlm.nih.gov/37827694/
3. 2024 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis. *Arthritis Rheumatol* 2025;77(9):1115–1135. PMID 40331662 (abstract read): treatment is continuous; pulse glucocorticoids, then an oral taper, with two additional immunosuppressive agents, continued for three to five years after a complete renal response. The detailed taper target and the response definitions used in the record were not read in the full text. https://pubmed.ncbi.nlm.nih.gov/40331662/
4. American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology* 2016;123(6):1386–1394. PMID 26992838 (abstract read): no more than 5.0 mg/kg real weight; baseline fundus examination; yearly screening with automated visual fields and SD-OCT after five years without major risk factors; kidney disease is a risk factor. https://pubmed.ncbi.nlm.nih.gov/26992838/
5. 2022 ACR Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. *Arthritis Rheumatol* 2023;75(3):333–348. PMID 36597810 (abstract read); CDC Adult Immunization Schedule by Medical Condition (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html). https://pubmed.ncbi.nlm.nih.gov/36597810/
6. 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheumatol* 2023;75(12):2088–2102. PMID 37845798 (abstract read): fracture-risk assessment with BMD as soon as possible after starting more than three months of glucocorticoids; drug treatment for medium or higher risk. https://pubmed.ncbi.nlm.nih.gov/37845798/
7. 2020 ACR Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. *Arthritis Care Res* 2020;72(4):461–488. PMID 32090466 (abstract read): effective contraception, conception during quiet disease on compatible medicines, and attention to antiphospholipid and anti-Ro/La status. https://pubmed.ncbi.nlm.nih.gov/32090466/
8. BENLYSTA (belimumab) prescribing information, DailyMed (label published September 2026): subcutaneous dosing for lupus nephritis, 400 mg once weekly for four doses, then 200 mg once weekly. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fa3c528-1777-4628-8a55-a69dae2381a3
9. CELLCEPT (mycophenolate mofetil) prescribing information, DailyMed (label published August 2026): complete blood counts weekly for the first month, twice monthly for the second and third months, then monthly for the rest of the first year; embryofetal toxicity and contraception requirements. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37241e87-4af4-4dc3-a1aa-ea6f20d8dc40
10. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), chronic kidney disease and hypertension monographs: potassium and creatinine two to four weeks after starting an ACE inhibitor or ARB; standardized office blood pressure; NSAID avoidance. https://patrickrutledge.github.io/topthirty/
11. IDSA/ESCMID International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women, 2010 update. *Clin Infect Dis* 2011;52(5):e103–e120. PMID 21292654. Used at the sick visit. https://pubmed.ncbi.nlm.nih.gov/21292654/
12. Medicare Preventive Services reference (Aether Forge, 2026), the preventive visit template (https://patrickrutledge.github.io/preventative_services/); U.S. Preventive Services Task Force A and B recommendations (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations); CDC Adult Immunization Schedule by Age (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html).

## Editorial resolutions

- **Index age and dates.** Index age 25. The brief suggested an index date in December 1950 or early 1951. Visits in 2026 can only map to January through October of a true year; with a shift of 75 the episode would fall from January 1951 onward, when the sources place her in hospital in Milledgeville and Atlanta and then on ACTH, and the synthetic outpatient visits would contradict that. A shift of 76 instead maps the index visit on April 13, 2026 to April 13, 1950, when she was 25, in the year the sources say her joint pain began and rheumatoid arthritis was suspected, and before the December 1950 illness in which lupus was diagnosed. The synthetic date of birth is March 25, 2001 (shift 76 years), keeping her birthday. The other visits (April 22 and 29, June 15, July 27, October 5, and October 26, 2026) map to the same days of 1950, all before that December. The index age of 25 matches the brief.
- **Diagnosis date.** Sources date her diagnosis to 1950 (PBS, New Georgia Encyclopedia, Hektoen), late 1950 in Atlanta (Pharos, Scribner), or January 1951 (a search summary of a Georgia Historical Society page, not used). The timeline records it as "1950, by December," approximate. A disability-studies article seen in search said a specialist told her in July 1952; it was not fetched and is not used.
- **The 1964 operation.** Sources describe it as surgery for a fibroid tumor (PBS, New Georgia Encyclopedia), removal of a benign abdominal tumor (Scribner), or a hysterectomy (Pharos). The claim says abdominal surgery for a bleeding fibroid and notes the hysterectomy in its interpretation; it is later than the episode and not used.
- **Avascular necrosis.** Crutches, hip pain, and her letter that her doctors blamed the steroid drugs for her "bone disintegration" are documented (**D**). The label avascular necrosis of the femoral head, and a possible effect on the jaw, are physicians' retrospective interpretation (**R**, probable); an early malar rash and Jaccoud arthropathy are **R**, possible. None is used as a finding in the modern episode, which instead keeps glucocorticoids low, starts a steroid-sparing drug at once, measures bone density, and teaches her to report hip pain.
- **Teaching contrast: disclosure.** Her mother chose not to tell her the diagnosis, and she learned it from a friend in 1951 (source 1, citing the biography). This is recorded as a documented claim linked to a later timeline event, without judgment. The synthetic episode tells her the diagnosis directly at the first chance, with teach-back and a written copy, and her advance directive asks that she always be told first. No modern statement, decision, or health fact is attributed to her mother or any other relative; her father's lupus appears only as documented family history, and the modern notes say only that she knows he had lupus.
- **Treatment choices.** Synthetic: ISN/RPS class III (A) lupus nephritis with activity 6 and chronicity 1, so that the episode teaches proliferative nephritis with a good prognosis; pulse methylprednisolone, prednisone tapered from 30 mg to 5 mg by six months, mycophenolate 2 g a day, and belimumab, which she chose over voclosporin (both are add-on options in EULAR 2023 and ACR 2024); hydroxychloroquine 300 mg, 5 mg/kg at 60 kg; losartan. Judgment call: Pneumocystis prophylaxis was discussed and not started, because the prednisone dose falls below 20 mg within six weeks and sulfonamides are avoided in lupus; a reviewer may prefer atovaquone. The responses (a ratio falling from 1.8 to 0.9 g/g at three months and 0.35 at six months) are synthetic and on the favorable side.
- **Contraception and pregnancy.** She chose a levonorgestrel intrauterine system before mycophenolate; with negative antiphospholipid antibodies estrogen was also an option. The six-month visit gives a pregnancy plan (azathioprine in place of mycophenolate, losartan stopped, hydroxychloroquine continued, anti-Ro and anti-La tests, low-dose aspirin from 12 weeks), all synthetic and not linked to her life.
- **Focused visits.** The four chronic-care follow-ups (diagnosis with the consultation, the biopsy result and treatment start, three months, and six months) are documented as focused visits on the 2019 EULAR/ACR criteria, EULAR 2023, ACR 2024, the AAO, ACR vaccination, ACR glucocorticoid-induced osteoporosis, and ACR reproductive health guidelines, the mycophenolate and belimumab labels, and the CMID kidney monograph. The rheumatology blood counts between visits are reported in prose, not as observations; the hepatitis, HIV, pregnancy, and urine culture results are reported in prose. One protocol deviation is recorded: potassium and creatinine two to four weeks after starting losartan were missed, found normal at the sick visit at seven and a half weeks, with the corrective action recorded.
- **Sick visit.** An unscheduled sick visit on June 15, 2026 (true frame June 15, 1950) for cystitis on mycophenolate, belimumab, and prednisone. It teaches the low threshold for culture and treatment on immunosuppression, a seven-day nitrofurantoin course, avoiding sulfonamides in lupus, not measuring urine protein during infection, and telling infection apart from a nephritis flare. It insinuates no undocumented real diagnosis.
- **Preventive visit.** An adult preventive visit (age 25, so `preventive_adult`) on October 5, 2026 (true frame October 5, 1950). Synthetic judgment calls: yearly cervical screening while immunosuppressed (a judgment based on the higher risk on immunosuppression, not a USPSTF interval); HPV and hepatitis B vaccination in childhood; the advance directive names no real person.
- **Consultation.** The rheumatology referral and the consultation by Rafael Okonjo-Strand, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the seven referral questions with what the record shows happened afterwards: classification by the 2019 criteria; a kidney biopsy, which showed class III; pulse and tapering glucocorticoids, mycophenolate with belimumab, hydroxychloroquine, and losartan; vaccination before immunosuppression; an intrauterine system before mycophenolate; DXA, vitamin D, avascular necrosis counseling, and a baseline eye examination; and family-history counseling.
- **Name.** The apostrophe in O'Connor is kept exactly. The generators write it as `&apos;` in the C-CDA and HTML and as a plain apostrophe in the notes; the cross-case name check matched it correctly. The alias "Mary Flannery O'Connor" appears in no other record; "O'Connor" alone appears in other records only as the surname of unrelated authors and is not used as an alias.
- **Other people.** The friend from whom she learned the diagnosis, the Atlanta kidney specialist, and her writing teachers are not named; no living person is named. The supporting people in the social history are unnamed and make no decisions.
- O'Connor died in 1964, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
